Healthcare
Medical
Pharmaceutical

Novartis

$86.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$3.08 (3.65%) Today
-$0.72 (-0.83%) After Hours

Why Robinhood?

You can buy or sell Novartis and other stocks, options, ETFs, and crypto commission-free!

About

Novartis AG, also called Novartis, is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. Read More The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Employees
125,161
Headquarters
Basel, Basel-Stadt (Basle Town)
Founded
1996
Market Cap
196.14B
Price-Earnings Ratio
16.47
Dividend Yield
2.15
Average Volume
2.27M
High Today
$88.44
Low Today
$86.33
Open Price
$86.50
Volume
1.72M
52 Week High
$96.31
52 Week Low
$72.30

Collections

Healthcare
Medical
Pharmaceutical
Manufacturing
Health
Technology

News

Reuters40m

For Anderson family, an early bet on SMA gene therapy

NEW YORK, May 24 (Reuters) - When Malachi Anderson was diagnosed with a rare and often deadly disease called spinal muscular atrophy (SMA) as an infant nearly four years ago, his parents Tina and Torence had a decision to make.

1
Wall Street Journal12m

At $2 Million, New Novartis Drug Is Priciest Ever

The world’s most expensive medicine is about to hit the market. A one-time treatment for a devastating infant muscle-wasting disease won approval from the U.S. Food and Drug Administration Friday. Its maker Novartis AG NVS 3.65% says the gene therapy will cost $2.125 million. The therapy, called Zolgensma, treats an inherited disease called spinal muscular atrophy, or SMA, whose victims typically die before the age of two if untreated. It is the latest gene therapy—a technique that introduces new DNA into...

20
Seeking Alpha52m

FDA OKs Novartis' alpelisib for certain type of breast cancer; shares up 4%

The FDA approves Novartis' (NVS +3.7% ) Piqray (alpelisib), a PI3K inhibitor, for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative PIK3CA-mutated advanced or metastatic breast cancer in patients who have progressed after receiving endocrine-based therapy.

22

Earnings

$1.20
$1.24
$1.28
$1.32
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 18, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.